Company intelligence / Profile preview
Bridge Therapeutics, Inc.
Birmingham, Alabama, United Statesbridgetherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Bridge Therapeutics is developing BT-219 (Bunalz™), a buprenorphine-naloxone combination using Catalent's Zydis® ODT delivery technology for opioid use disorder, and BT-205 (Bucam™), a patented combination of buprenorphine and meloxicam for chronic pain. Both products are pursuing FDA approval through the 505(B)(2) process.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Camargo Pharmaceutical ServicesCatalent (for Zydis® technology)
Beyond the preview
Go deeper on Bridge Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bridge Therapeutics, Inc..